Showing posts with label multiple sclerosis diagnosis. Show all posts
Showing posts with label multiple sclerosis diagnosis. Show all posts

Wednesday 11 April 2018

Multiple Sclerosis Assessment and Therapeutics Analysis Forecasts To H1 2017

Summary 
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510557-multiple-sclerosis-pipeline-review-h1-2017

Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Multiple Sclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Multiple Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 9, 30, 32, 1, 168, 34 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 47 and 2 molecules, respectively.
Multiple Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

  Table of Contents 
Table of Contents 2
Introduction 9
Multiple Sclerosis - Overview 10
Multiple Sclerosis - Therapeutics Development 11
Multiple Sclerosis - Therapeutics Assessment 48
Multiple Sclerosis - Companies Involved in Therapeutics Development 70
Multiple Sclerosis - Drug Profiles 160
Multiple Sclerosis - Dormant Projects 746
Multiple Sclerosis - Discontinued Products 763
Multiple Sclerosis - Product Development Milestones 766
Appendix 778
List of Tables
Number of Products under Development for Multiple Sclerosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
    
  .Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510557-multiple-sclerosis-pipeline-review-h1-2017
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)